Public-registry site landscape for NCT07729956, a Triple-Negative Breast Cancer (TNBC) study sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07729956 (registry record) |
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Condition(s) | Triple-Negative Breast Cancer (TNBC) |
| Phase | PHASE3 |
| Listed sites | 1 |
| Site countries | China |
At Fudan University Shanghai Cancer Center — one of the facilities listed on this trial — 16 other studies are actively recruiting Triple-Negative Breast Cancer (TNBC) patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07729956 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →